January 16, 2020 Biopharma venture financing retreats, but not by much Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
January 16, 2019 Smaller groups await Bristol-Myers Squelgene fallout Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?
